Following a positive recommendation from the European Medicines Agency (EMA), the European Commission has officially approved Ascendis Pharma's Lonapegsomatropin, Ascendis announces in a press release.
Lonapegsomatropin, which is developed under the name Transcon hGH and marketed in the US as Skytrofa, is a once-weekly injection for pediatric patients, and the approval follows a positive opinion from the EMA's expert committee, the CHMP, in November.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.